Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Partnering Opens 600x60px
Document › Details

Sygnature Discovery Ltd.. (11/8/18). "Press Release: Sygnature Discovery Announces Multi-target Drug Discovery Deal with Sitryx Therapeutics".

Organisations Organisation Sygnature Discovery Ltd.
  Organisation 2 Sitryx Therapeutics Ltd.
Products Product drug discovery services
  Product 2 immunotherapy
Index term Index term Sitryx Therapeutics–Sygnature Discovery: drug discovery services, 201811– collab service multi-target drug discovery in I-O + immuno-inflammation
Persons Person Hirst, Simon (Sygnature Discovery 201112 CEO + Founder)
  Person 2 Weir, Neil (Sitryx Therapeutics 201804– CEO before UCB SVP Discovery)
     


Sitryx Therapeutics selects Sygnature Discovery for multi-target, integrated drug discovery collaboration.

The energetic status of cells has been shown to be pivotal in controlling the behaviour of disease associated cells in immuno-oncology and immuno-inflammation. Correcting immune cell function and/or inhibiting tumour cell growth through targeting metabolic pathways has the potential to deliver new complementary and highly-differentiated approaches to treat a wide range of severe diseases.

Sitryx’s proprietary science is led by a highly-experienced management team, supported by GlaxoSmithKline‘s drug discovery experience and world-class academic founders, in addition to Sygnature’s significant expertise in immuno-oncology and immunology drug discovery. Sitryx Therapeutics was founded by six world-leading researchers in the field of immunology and immuno-regulation, including Houman Ashrafian, Luke O’Neill, Jonathan Powell, Jeff Rathmell, Michael Rosenblum and Paul Peter Tak.

Commenting on the collaboration, Sygnature’s CEO and Founder, Dr Simon Hirst said: “We are pleased to have been selected by Sitryx to support their ground-breaking research efforts to develop disease-modifying therapeutics across multiple biological targets in immuno-oncology and immuno-inflammation. Our considerable in-house knowledge of immuno-oncology and immunology discovery will enable us to efficiently navigate these complex areas of biology to support the identification and optimisation of novel and selective small molecules while developing a deep understanding of their mode-of-action.”

Dr Neil Weir, Sitryx’s CEO, said, “Sygnature Discovery has an established reputation as a provider of premium integrated drug discovery and pre-clinical services and the Sitryx team has an extensive track record of success in the discovery and development of novel drugs. We will combine our considerable know-how and expertise to deliver new, highly-effective disease-modifying therapeutics in immuno-oncology and immuno-inflammation.”

To find out more, please contact 0115 941 5401.

   
Record changed: 2019-02-20

Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Partnering Opens 600x60px

More documents for Sygnature Discovery Ltd.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px




» top